The current approach to the treatment of the patients with metastatic colorectal cancer

Authors: J. Halámková 1,2;  J. Tomášek 1;  S. Rybníčková 3;  D. Adámková Krákorová 1;  B. Bencsiková 1;  I. Kiss 1
Authors‘ workplace: Klinika komplexní onkologické péče Lékařské fakulty MU a MOÚ Brno, přednosta prof. MU Dr. Rostislav Vyzula, CSc. 1;  Ústav lékařské etiky Lékařské fakulty MU Brno, přednosta doc. Mgr. Josef Kuře, Dr. phil. 2;  Oddělení radiologie Masarykova onkologického ústavu Brno, přednostka prim. MU Dr. Helena Bartoňková 3
Published in: Vnitř Lék 2013; 59(10): 903-908
Category: Review


Colorectal cancer is one of the most common malignant tumors. Despite the constant promotion of prevention remains around 20– 30% of cases dia­gnosed in the metastatic stage and approximately 50– 60% of patients developed the late dissemination. In 80– 90% of them we can find already unresectable metastases. Although surgical treatment is basic modality of therapy, with using mo­dern targeted therapy in combination with chemotherapy we can achieve long‑term complete remission in the cases of advanced tumor and we can significantly prolonged the life of patients with this disease now. About 40– 50% patients in advanced stages who underwent metastasectomy survives 5-years and 10‑year survival rate is up to 25%. When administered systemic treatment median overall survival in these cases reaches around 24 months.

Key words:
colorectal cancer –  liver metastases –  conversion therapy –  targeted treatment


1. Ústav zdravotnických informací a statistiky ČR, Národní zdravotnický informační systém (NZIS), Národní onkologický registr (NOR), [online, citace 24. 3. 2013]. Dostupné z: http:/ / publikace/ novotvary‑ 2009.

2. Muratore A, Zorzi D, Bouzari H et al. Asymptomatic colorectal cancer with un‑ resectable liver metastases: immediate colorectal resection or up‑ front systemic chemotherapy? Ann Surg Oncol 2007; 14: 766– 770.

3. Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver‑ only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243– 9249.

4. Vyzula R, Žaloudík J. Rakovina tlustého střeva a konečníku, vybrané kapitoly. Praha: Maxdorf 2007.

5. Rees M, Tekkis PP, Welsh FK et al. Evaluation of long‑term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247: 125– 135.

6. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1,001 consecutive cases. Ann Surg 1999; 230: 309– 321.

7. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23: 2038– 2048.

8. Rothenberg M, Oza A, Bigelow R et al. Superiority of oxaliplatin and fluorouracil‑ leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil‑ leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059– 2069.

9. Saltz L, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905– 914.

10. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5– flourouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised phase III trials. Br J Cancer 2004; 90: 1190– 1197.

11. Van den Eynde M, Hendlisz A. Treatment of colorectal liver metastases: a review. Rev Recent Clin Trials 2009; 4: 56– 62.

12. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first‑line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670– 1676.

13. Bennouna J, Sastre J, Arnold D et al. ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 tril. Lancet Oncology 2013; 14: 29– 37.

14. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin‑based regimen. J Clin Oncol 2012; 30: 3499– 3506.

15. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo‑ controlled, phase 3 trial. Lancet 2013; 381: 303– 312.

16. Masi G, Cupini S, Marcucci L et al. Treatment with 5- fluorouracil/ folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006; 13: 58– 65.

17. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007– 1016.

18. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38– 47.

19. Heinemann V, Fischer von Weikersthal L, Decker T et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first‑line treatment of KRAS‑ wild type metastatic colorectal cancer: German AIO study KRK‑ 0306 (FIRE‑ 3). J Clin Oncol 2013; 31 (Suppl): abstract LBA3506.

20. Zorzi D, Laurent A, Pawlik TM et al. Chemotherapy‑associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274– 286.

21. Wicherts DA, De Haas RJ, Andreani P et al. Impact of portal vein embolization on long‑term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 2010; 97: 240– 250.

22. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalised approach to clinical decision making. Ann Oncol 2012; 23: 2479– 2516.

23. Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20: 985– 992.

24. Primrose JN, Falk S, Finch‑ Jones M et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k‑ RAS wild‑type patients with operable metastases from colorectal cancer: The new EPOC study. J Clin Oncol 2013; 31 (Suppl): abstract 3504.

25. Reddy SK, Pawlik TM, Zorzi D et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi‑institutional analysis. Ann Surg Oncol 2007; 14: 3481– 3491.

26. De Jong MC, Van Dam RM, Maas M et al. The liver‑ first approach for synchronous colorectal liver metastasis: a 5‑year single‑centre experience. HPB (Oxford) 2011; 13: 745– 752.

27. Šubrt Z, Ferko A, Čečka F et al. Současné možnosti chirurgické léčby ložiskového postižení jater a pankreatu. Vnitř Lék 2011; 57: 356– 363.

28. Fernandez FG, Ritter J, Goodwin JW et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845– 853.

29. Ribero D, Wang H, Donadon M et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‑based chemotherapy for colorectal liver metastases. Cancer 2007; 110: 2761– 2767.

30. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, Capecitabine, and Oxaliplatin as Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer. J Clin Oncol 2008; 26: 1830– 1835.

31. Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976– 4982.

Diabetology Endocrinology Internal medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account